Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Manufactures pharmaceuticals

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans. This results in a diversified product pipeline of complex generic, follow-on biologic and novel drugs. The Company's two most advanced complex generic product candidates target marketed products, which were originally approved by the United States Food and Drug Administration as New Drug Applications. M-Enoxaparin is designed to be a generic version of Lovenox (enoxaparin sodium injection), a low-molecular weight heparin used to prevent and treat deep vein thrombosis. Its second major generic product candidate is M356, a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Zymergen, Inc. engages in the design, development, and commercialization of bio-based products. Its products include electronic films, repellent products, and agriculture products such as traditional synthetic nitrogen fertilizers and traditional chemical-based crop protection products. The company was founded by Zachariah Serber, Jed Dean and Joshua J. Hoffman in 2013 and is headquartered in Emeryville, CA.

Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom.

AGC Biologics, Inc. develops therapeutic proteins for early clinical trials. The firm offers integrated cGMP manufacturing services using microbial fermentation and mammalian cell culture processes. The company was founded in 2007 and is headquartered in Bothell, WA.

MedImmune Ltd. engages in research, development and exploitation of products in the field of molecular engineering. The company was founded on December 11, 1989 and is headquartered in Cambridge, the United Kingdom.

Selexis SA provides research and development services in the field of mammalian cell lines. Its product SUREtechnology Platform improves the way cells are used in the discovery, development and manufacturing of recombinant proteins and drugs. The company was founded by Nicolas Mermod, Igor Edouard Fisch and Peter A. Pfister in 2001 and is headquartered in Plan-les-Ouates, Switzerland.

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Qyuns Therapeutics Co., Ltd. engages in the innovation and production of antibody drugs for the treatment of immune-related diseases and therapeutic antibody drugs. Its therapeutic areas include skin diseases, inflammatory rheumatic, inflammatory bowel, and inflammatory respiratory. The company was founded by Wen Wan Qiu on June 16, 2015 and is headquartered in Taizhou, China.

Seikagaku Corp. manufactures pharmaceuticals and medical devices with glycoconjugates; specifically, glycosaminoglycans (GAG) such as hyaluronic acid; as well as enzymes that act on GAG. It operates through the following segments: Pharmaceuticals and Limulus Amebocyte Lysate (LAL). The Pharmaceuticals segment develops and supplies intra-articular injections for improving joint functions, cross-linked hyaluronate hydrogel for knee osteoarthritis, opthalmic surgical aids, and surgical aids for endoscopic mucosal resection. The LAL segment manufactures and sells endotoxin-detecting reagents in Japan and overseas. The company was founded on June 2, 1947 and is headquartered in Tokyo, Japan.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Beijing Mabworks Biotech Co., Ltd. engages in the discovery, development, manufacturing and commercialization of therapeutic antibodies. It develops antibody drugs and macromolecular biological drugs. The firm’s products include MIL60, MIL62, MIL86, MBS301, MIL77, and MIL93. The company was founded on February 27, 2003 and is headquartered in Beijing, China.

Sigma Aldrich Co. Ltd. engages in the science and technology company. Its products include analytical standards, gas chromatography, spectroscopy, acids and bases, catalysis and inorganics, organometallics, solvents, antibodies, biochemical and reagents, cell biology, microbiology, and polymer sciences. It also offers basic research, product and process development, manufacturing and production, and regulatory compliance services. The company was founded on December 10, 1987 and is headquartered in Gillingham, the United Kingdom.

Jiangsu Zhongxin Pharmaceutical Co., Ltd., established on 2011-03-30, Business scope includes research and development of pharmaceutical products,Production,technology transfer,technical consulting,Technical Services;medical instruments(Ikind,IIkind,IIIkind)and in vitro diagnostic reagents(Ikind,IIkind,IIIkind)research and development,Production;Healthy food,Production of health care products;Sales of self-produced products;Healthy food,Health Supplies,retail of cosmetics,wholesale,Import and export and commission agency(except auction).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Lek Pharmaceuticals dd, a subsidiary of Novartis AG, is a company headquartered in Ljubljana, Slovenia, that develops, manufactures and markets drugs and pharmaceutical products. Robert Ljoljo is the CEO, in this role since 2019. On November 21, 2002 Novartis AG acquired Lek Pharmaceuticals dd for $689.24 million.

Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.